Systemic pharmacokinetics of rifaximin in volunteers with shigellosis

David N. Taylor, Robin McKenzie, Anna Durbin, Colleen Carpenter, Robert Haake, A. Louis Bourgeois

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Rifaximin is an oral antibiotic indicated for treatment of traveler's diarrhea. Rifaximin pharmacokinetics were evaluated in individuals challenged with Shigella flexneri. Peak plasma rifaximin concentrations were low after nine consecutive doses, and no accumulation was observed. Rifaximin serum levels were minimal and similar to those previously reported in studies of healthy volunteers.

Original languageEnglish (US)
Pages (from-to)1179-1181
Number of pages3
JournalAntimicrobial agents and chemotherapy
Issue number3
StatePublished - Mar 2008

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Systemic pharmacokinetics of rifaximin in volunteers with shigellosis'. Together they form a unique fingerprint.

Cite this